iTeos Therapeutics (ITOS) News Today $5.39 -0.31 (-5.44%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$5.39 0.00 (0.00%) As of 04/4/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period iTeos Therapeutics (ITOS) Gets a Buy from Piper SandlerMarch 31, 2025 | markets.businessinsider.comiTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025March 25, 2025 | globenewswire.comShort Interest in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Declines By 19.0%iTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) was the target of a large decline in short interest in February. As of February 28th, there was short interest totalling 1,280,000 shares, a decline of 19.0% from the February 13th total of 1,580,000 shares. Based on an average daily trading volume, of 362,400 shares, the short-interest ratio is presently 3.5 days. Approximately 3.9% of the shares of the stock are sold short.March 19, 2025 | marketbeat.comWall Street Analysts Think iTeos Therapeutics (ITOS) Could Surge 212.5%: Read This Before Placing a BetMarch 13, 2025 | msn.comHC Wainwright Issues Optimistic Estimate for ITOS EarningsiTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) - Stock analysts at HC Wainwright increased their Q1 2025 earnings estimates for iTeos Therapeutics in a research report issued on Thursday, March 6th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per shaMarch 10, 2025 | marketbeat.comResearch Analysts Offer Predictions for ITOS Q1 EarningsiTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) - Investment analysts at Wedbush boosted their Q1 2025 earnings per share (EPS) estimates for shares of iTeos Therapeutics in a research report issued on Wednesday, March 5th. Wedbush analyst D. Nierengarten now anticipates that the company wilMarch 10, 2025 | marketbeat.comFY2029 Earnings Estimate for ITOS Issued By HC WainwrightiTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) - Investment analysts at HC Wainwright issued their FY2029 earnings per share estimates for shares of iTeos Therapeutics in a research note issued to investors on Thursday, March 6th. HC Wainwright analyst S. Ramakanth anticipates that the compMarch 8, 2025 | marketbeat.comWells Fargo & Company Has Lowered Expectations for iTeos Therapeutics (NASDAQ:ITOS) Stock PriceWells Fargo & Company cut their price objective on shares of iTeos Therapeutics from $19.00 to $17.00 and set an "overweight" rating on the stock in a research report on Thursday.March 7, 2025 | marketbeat.comiTeos Therapeutics (NASDAQ:ITOS) Given New $15.00 Price Target at JPMorgan Chase & Co.JPMorgan Chase & Co. decreased their price objective on shares of iTeos Therapeutics from $22.00 to $15.00 and set an "overweight" rating on the stock in a research report on Thursday.March 7, 2025 | marketbeat.comiTeos Therapeutics (NASDAQ:ITOS) Receives Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $46.00 price objective on shares of iTeos Therapeutics in a research report on Thursday.March 7, 2025 | marketbeat.comiTeos Therapeutics price target lowered to $17 from $19 at Wells FargoMarch 7, 2025 | markets.businessinsider.comiTeos Therapeutics (NASDAQ:ITOS) Receives Outperform Rating from WedbushWedbush reissued an "outperform" rating and set a $25.00 target price on shares of iTeos Therapeutics in a research report on Wednesday.March 6, 2025 | marketbeat.comiTeos Therapeutics Full Year 2024 Earnings: In Line With ExpectationsMarch 6, 2025 | finance.yahoo.comiTeos Therapeutics (NASDAQ:ITOS) Announces Quarterly Earnings ResultsiTeos Therapeutics (NASDAQ:ITOS - Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.14) by $0.13.March 6, 2025 | marketbeat.comiTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatesMarch 5, 2025 | globenewswire.comiTeos Therapeutics: Decimated By Collateral Events, Good Chances Of Success NeverthelessFebruary 27, 2025 | seekingalpha.comiTeos Therapeutics (ITOS) to Release Earnings on WednesdayiTeos Therapeutics (NASDAQ:ITOS) will be releasing earnings before the market opens on Wednesday, March 5, Financial Modeling Prep reports.February 26, 2025 | marketbeat.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) Short Interest UpdateiTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) was the recipient of a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 1,410,000 shares, a growth of 5.2% from the January 15th total of 1,340,000 shares. Based on an average trading volume of 419,500 shares, the short-interest ratio is currently 3.4 days. Approximately 4.6% of the shares of the company are short sold.February 17, 2025 | marketbeat.comPeapod Lane Capital LLC Takes Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS)Peapod Lane Capital LLC purchased a new position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 108,853 shares of the company's stock, valued at approximately $836,000. Peapod Lane CaFebruary 13, 2025 | marketbeat.comITOS stock touches 52-week low at $7.09 amid market challengesFebruary 11, 2025 | msn.comWe Think iTeos Therapeutics (NASDAQ:ITOS) Needs To Drive Business Growth CarefullyFebruary 4, 2025 | finance.yahoo.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) Short Interest Down 21.1% in JanuaryiTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) was the recipient of a significant drop in short interest during the month of January. As of January 15th, there was short interest totalling 1,500,000 shares, a drop of 21.1% from the December 31st total of 1,900,000 shares. Approximately 4.9% of the shares of the company are short sold. Based on an average daily volume of 556,500 shares, the days-to-cover ratio is currently 2.7 days.January 30, 2025 | marketbeat.com5 US Longevity and Anti-aging Stocks to Watch in 2025January 24, 2025 | msn.comiTeos Therapeutics: Promising Phase 2 Data Boosts Buy Rating on Lead Asset Belrestotug CombinationJanuary 17, 2025 | markets.businessinsider.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) Short Interest Down 21.1% in DecemberiTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) saw a large drop in short interest during the month of December. As of December 31st, there was short interest totalling 1,500,000 shares, a drop of 21.1% from the December 15th total of 1,900,000 shares. Based on an average daily volume of 556,500 shares, the short-interest ratio is presently 2.7 days. Currently, 4.9% of the company's shares are short sold.January 16, 2025 | marketbeat.comiTeos Therapeutics (NASDAQ:ITOS) Earns "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $21.00 target price on shares of iTeos Therapeutics in a research report on Thursday.January 16, 2025 | marketbeat.comiTeos Therapeutics outlines business updates, strategies for 2025January 11, 2025 | markets.businessinsider.comiTeos Therapeutics' (ITOS) "Outperform" Rating Reaffirmed at WedbushWedbush reiterated an "outperform" rating and issued a $25.00 price objective on shares of iTeos Therapeutics in a report on Friday.January 10, 2025 | marketbeat.comiTeos Announces 2025 Strategic Priorities and Anticipated MilestonesJanuary 10, 2025 | markets.businessinsider.comState Street Corp Increases Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)State Street Corp increased its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 21.9% during the third quarter, according to its most recent filing with the SEC. The fund owned 1,175,353 shares of the company's stock after buying an additional 211,452 shares during the quarter. StaDecember 26, 2024 | marketbeat.comiTeos Therapeutics (NASDAQ:ITOS) Price Target Lowered to $19.00 at Wells Fargo & CompanyWells Fargo & Company cut their price objective on shares of iTeos Therapeutics from $31.00 to $19.00 and set an "overweight" rating for the company in a research report on Thursday.December 19, 2024 | marketbeat.comiTeos Therapeutics: A Perhaps Unjustified Decline To End 2024December 17, 2024 | seekingalpha.comInupadenant “deprioritised” by iTeos in favour of pipeline TIGIT therapyDecember 15, 2024 | finance.yahoo.comStrategic Focus on Belrestotug Drives Buy Rating for iTeos Therapeutics with Adjusted Price Target of $21December 14, 2024 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for iTeos Therapeutics (NASDAQ:ITOS)HC Wainwright reissued a "buy" rating and issued a $21.00 target price on shares of iTeos Therapeutics in a research note on Friday.December 13, 2024 | marketbeat.comiTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology CongressDecember 12, 2024 | globenewswire.comRA Capital Management L.P. Sells 332,548 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS)RA Capital Management L.P. lessened its holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 9.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,184,711 shares of the company's stock after selling 332,December 5, 2024 | marketbeat.comReadystate Asset Management LP Has $1.73 Million Stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS)Readystate Asset Management LP raised its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 97.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 169,819 shares of the company's stock after acquiring an adDecember 5, 2024 | marketbeat.comVestal Point Capital LP Has $10.47 Million Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)Vestal Point Capital LP trimmed its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 41.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,025,000 shares of the company's stock after selling 725,00November 29, 2024 | marketbeat.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Bought by Algert Global LLCAlgert Global LLC grew its position in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 92.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 256,139 shares of the company's stock after buying aNovember 27, 2024 | marketbeat.comiTeos to Participate in Upcoming Investor ConferencesNovember 26, 2024 | globenewswire.comMatthew Gall Acquires 5,000 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) StockNovember 20, 2024 | insidertrades.comPromising Developments and Strategic Positioning Drive Buy Rating for iTeos TherapeuticsNovember 15, 2024 | markets.businessinsider.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next YearNovember 15, 2024 | finance.yahoo.comiTeos Therapeutics' (ITOS) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $46.00 price objective on shares of iTeos Therapeutics in a research report on Friday.November 15, 2024 | marketbeat.comWedbush Predicts Stronger Earnings for iTeos TherapeuticsiTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) - Equities researchers at Wedbush boosted their FY2024 earnings per share (EPS) estimates for iTeos Therapeutics in a research note issued on Tuesday, November 12th. Wedbush analyst D. Nierengarten now anticipates that the company will post earNovember 15, 2024 | marketbeat.comiTeos Therapeutics: Potential Upside from Adenosine Program Amidst TIGIT ChallengesNovember 14, 2024 | markets.businessinsider.comiTeos Therapeutics Reports Q3 2024 Financial ResultsNovember 14, 2024 | markets.businessinsider.comStrategic Catalysts and Financial Stability Underpin Buy Rating for iTeos TherapeuticsNovember 13, 2024 | markets.businessinsider.comiTeos Reports Third Quarter 2024 Financial Results and Provides Business UpdatesNovember 12, 2024 | globenewswire.com Remove Ads Get iTeos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITOS and its competitors with MarketBeat's FREE daily newsletter. Email Address ITOS Media Mentions By Week ITOS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ITOS News Sentiment▼0.840.61▲Average Medical News Sentiment ITOS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ITOS Articles This Week▼12▲ITOS Articles Average Week Remove Ads Get iTeos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITOS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NRIX News Today VIR News Today PAHC News Today XERS News Today OCS News Today ZYME News Today RCUS News Today PHVS News Today DAWN News Today CDMO News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ITOS) was last updated on 4/5/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredIt’s Time to Buy Elon’s “ChatGPT Killer”Elon Musk’s new AI model is blowing everyone’s mind. It has been called “a game-changer in AI innovation”.....Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iTeos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iTeos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
